A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.
Saved in:
| Title: | A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. |
|---|---|
| Authors: | Jo H; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Hong J; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kim H; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kim HR; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kwon GY; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kang KA; Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Park SY; Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kim CK; Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Park BK; Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Chung JH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Song W; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kang M; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Sung HH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Jeon HG; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Jeong BC; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Seo SI; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Jeon SS; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Lee HM; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Park SH; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. |
| Source: | Frontiers in oncology [Front Oncol] 2022 Apr 28; Vol. 12, pp. 874385. Date of Electronic Publication: 2022 Apr 28 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2022.874385 |
